GC Biopharma Corp. (KRX:006280)
South Korea flag South Korea · Delayed Price · Currency is KRW
130,500
+3,400 (2.68%)
Aug 28, 2026, 3:30 PM KST

GC Biopharma Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-13,896-4,674-26,280-26,63265,453123,212
Depreciation & Amortization
88,15487,65581,03475,89965,09655,904
Loss (Gain) From Sale of Assets
-75,426-40,8672,5112,919-40,657-6,991
Asset Writedown & Restructuring Costs
94,86194,77018,088---
Loss (Gain) From Sale of Investments
-5,0169,380-6,665-1,209660333
Loss (Gain) on Equity Investments
18,612-14,58227,46438,43118,099-81,533
Provision & Write-off of Bad Debts
3,1514,3541,0792,7892,2466,980
Other Operating Activities
18,657-11,261-6,5942,64917,11947,052
Change in Accounts Receivable
-9,248-27,41352,815-47,09313,219-10,756
Change in Inventory
-34,637-124,673-229,626-69,2341,721-14,919
Change in Accounts Payable
-19,57119,10112,07722,6894,011-16,463
Change in Other Net Operating Assets
95,502107,67320,637-6,681-27,81323,160
Operating Cash Flow
161,14499,463-53,460-5,473119,154125,979
Operating Cash Flow Growth
-----5.42%250.20%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-95,382-72,362-31,992-79,087-57,996-102,321
Sale of Property, Plant & Equipment
2,1142,109791.341,3191,540565.21
Cash Acquisitions
-9,151-62,261---74,05311,918
Divestitures
47,035-215.13---
Sale (Purchase) of Intangibles
-32,705-31,790-9,602-45,914-36,694-21,143
Investment in Securities
-50,926-26,828-24,226-25,139-31,332-30,734
Other Investing Activities
973.4957.112,269-1,423-723.710,133
Investing Cash Flow
-133,630-186,790-67,894-150,243-205,259-132,077

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-1,053,0631,221,1401,188,247806,151869,500
Long-Term Debt Issued
-168,555279,3875,00030,608209,429
Total Debt Issued
1,450,0841,221,6181,500,5271,193,247836,7591,078,929
Short-Term Debt Repaid
--1,067,201-1,169,646-1,059,800-721,740-992,600
Long-Term Debt Repaid
--24,142-217,342-9,419-135,590-102,423
Total Debt Repaid
-1,516,649-1,091,343-1,386,988-1,069,219-857,330-1,095,023
Net Debt Issued (Repaid)
-66,565130,275113,538124,028-20,571-16,094
Dividends Paid
-18,858-18,831-19,532-24,825-23,985-18,511
Other Financing Activities
137.36136.15-160.891,30842,075-6,665
Financing Cash Flow
-85,286111,58093,845100,512-2,481-41,270

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
8,9032,556366.22-455.397,8911,141
Miscellaneous Cash Flow Adjustments
-0-----
Net Cash Flow
-48,86926,809-27,143-55,660-80,694-46,228

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
65,76227,101-85,452-84,56061,15823,658
Free Cash Flow Growth
----158.51%-
Free Cash Flow Margin
3.22%1.36%-5.09%-5.20%3.57%1.54%
Free Cash Flow Per Share
5761.882374.52-7487.16-7408.975358.562072.84
Levered Free Cash Flow
94,644-2,151-119,077-166,64252,929-10,238
Unlevered Free Cash Flow
127,14329,284-93,803-148,84064,424-2,425

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
37,87738,33238,13924,08019,37813,546
Cash Income Tax Paid
8,99211,1412,46819,03337,34918,867
Change in Working Capital
32,046-25,312-144,097-100,319-8,862-18,978